Day: May 4, 2021

Standard Uranium’s projects in the Athabasca BasinStandard Uranium’s projects in the Athabasca BasinStandard Uranium Davidson River ProjectStandard Uranium Davidson River ProjectVANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — Standard Uranium Ltd. (“Standard Uranium” or the “Company”) (TSX-V: STND) (OTCQB: STTDF) (Frankfurt: FWB:9SU) is pleased to provide an update on its plans for the upcoming phase II summer drilling program at its flagship 25,886-hectare Davidson River Uranium Project (the “Project”). The Company concluded the Phase II winter program at the Project on March 29, 2021. Based on positive indications from the winter drill program, the Company announced on March 29, 2021 it would quadruple the summer program to 10,000 metres. Full details of the news release...

– Highest dose cohorts confirm and extend previously-reported 3 mg/kg IV cohort data –– 10 mg/kg IV dose provides full receptor occupancy through Day 71 and complete suppression of TDAR after KLH challenge and re-challenge through at least Day 57 –– 5 mg/kg SC dose provides full receptor occupancy through Day 43 and complete suppression of TDAR after KLH challenge through at least Day 29 –– Plan to initiate Phase 2 proof-of-concept trial in patients in 2H 2021 – HAMILTON, Bermuda, May 04, 2021 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced positive final data from the Phase 1 clinical trial of KPL-404 in healthy...

MCI’s new luxury coach provides unmatched design, EV performance, passenger experience, warranty, and infrastructure supportMCI’s new luxury coachMCI’s new luxury coach provides unmatched design, EV performance, passenger experience, warranty, and infrastructure supportWINNIPEG, Manitoba, May 04, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that its subsidiary Motor Coach Industries (“MCI”) has unveiled the new zero-emission, battery-electric J4500 CHARGE™ coach. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/26c6d288-ddbb-4cb1-9f49-5bfec1859316 YouTube link: https://www.youtube.com/watch?v=ri-qgxgO-Ms The...

WASHINGTON, May 04, 2021 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Michael Rachlin as a Senior Managing Director in the firm’s Valuation & Financial Advisory Services practice within the Corporate Finance & Restructuring segment. Mr. Rachlin, who will be based in New York, is an expert in life sciences, advising clients through their most critical transaction and transformation challenges. In his new role, Mr. Rachlin will lead life sciences industry efforts in the Valuation & Financial Advisory Services practice, helping clients in the biopharmaceutical, medical technology and cannabis industries evaluate transaction opportunities and larger growth-related initiatives, as well as valuation, deal modeling and strategic alternatives. “Michael is an expert at taking a dynamic...

AUBURN HILLS, Mich., May 04, 2021 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP), a leading global provider of merchandising and marketing services, announced that it has increased and extended the terms of its current line of credit. Under the more favorable terms of the amendment, the maximum amount of the line of credit increased by $2 million to $18 million and the length of the term was extended by 18 months to October 2023. In addition, the minimum interest rate decreased by 150 basis points to 5.25% and facility and early termination fees were substantially reduced. “We were able to increase the commitment amount while gaining more favorable terms and conditions, which will result in more than a 20% reduction in the interest rate, provide increased financial capacity and greater flexibility to support our growth initiatives,”...

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on May 11, 2021. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 9497433. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days. About Otonomy Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery...

Progenity survey shows more women know their baby’s “fruit size” than the key indicator of a common pregnancy complication Preeclampsia Awareness Month aims to educate women about the potentially deadly condition and recent advancements in diagnostic risk assessment SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) — May is Preeclampsia Awareness Month, and a recent survey is underscoring a stark need for more education around the second-most common cause of maternal mortality in the United States. The survey of nearly 800 women, including expectant mothers, new mothers within the last year, and those who are considering pregnancy, was conducted by Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women’s health. The results showed...

– Important for Patients Who Cannot Swallow Oral Capsules – NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the intravenous formulation (IV) of TPOXX®. The proposed indication, for the treatment of human smallpox disease in adults and pediatric patients weighing 13 kg or more, is the same as what was approved by the FDA in July 2018 for the oral formulation of TPOXX. The IV formulation will enable those patients who are too sick or unable to swallow capsules to be treated with TPOXX, thereby adding a significant new patient population. “This is our first application for regulatory approval...

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will be presenting at Canaccord Genuity’s 5th Annual Global Cannabis Conference on Tuesday, May 11th, which is being held virtually this year. Details on the conference and how to participate are below. Conference Details Date: Tuesday, May 11th, 2021 Presentation Details: Tuesday, May 11th at 2:30-2:55pm EDT Presentation Link: https://wsw.com/webcast/canaccord55/inm/2252448 Eric A. Adams and Bruce Colwill, InMed’s Chief Financial Officer, will also be conducting 1×1 meetings throughout...

–Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development– –Topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis on track for mid-2021– LEXINGTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today reported financial results for the first quarter ended March 31, 2021. “Kaleido is off to a strong start in 2021 marked by positive results from our 350-patient clinical study with KB109 in outpatients with mild-to-moderate COVID-19 and a...